DJIA 17,976.31 263.65 1.49%
NASDAQ 4,947.44 56.22 1.15%
S&P 500 2,086.24 25.22 1.22%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

62.52 -0.81 (-1.28%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ALKS $62.52 -1.28%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $63.60
Previous Close $63.33
Daily Range $61.97 - $64.21
52-Week Range $38.49 - $75.17
Market Cap $9.3B
P/E Ratio -301.57
Dividend (Yield) $0.00 (0.0%)
Volume 1,410,414
Average Daily Volume 1,639,789
Current FY EPS -$1.03




Drug Makers

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website:

News & Commentary Rss Feed

This Could Be Game-Changing News in the Battle Against Multiple Sclerosis

Multiple sclerosis affects more than 400,000 people in the United States and around 2.5 million people globally. That's why this potentially game-changing study's results are so promising and important.

Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog

Alkermes 'Taking A Pause,' Citi Says

Top Analyst Upgrades and Downgrades: Cisco, EMC, GameStop, Novavax, Tesla, Yahoo and More

Jeff Cooper: Indiscriminate Buying Begets Indiscriminate Selling

Sometimes technical analysis and time cycle work set up in a very compelling manner.

Interesting ALKS Put And Call Options For November 20th

UPDATE: Morgan Stanley Downgrades Alkermes As Good News Is Appreciated

Top Analyst Upgrades and Downgrades: Amarin, CONSOL, Garmin, GNC, HP, Peabody, Windstream and More

Analysts' Actions: Alkermes, GNC, Hewlett-Packard and More

Alkermes Streamlines Operations, Revises 2015 Guidance - Analyst Blog

Value in Good Management; Biotechs Are Feeling Better: Jim Cramer's Best Blogs

See More ALKS News...

ALKS's Top Competitors

ALKS $62.52 (-1.28%)
Current stock: ALKS
AMGN $164.31 (1.05%)
Current stock: AMGN
GILD $100.69 (-0.31%)
Current stock: GILD
BIIB $431.62 (0.41%)
Current stock: BIIB